Clinical Trial Update: Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for LVGN7409, a CD40 agonist antibody, evaluating it as a single agent and in combination therapies for advanced or metastatic can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• LVGN7409

Snippet

Sponsor: Lyvgen Biopharma Holdings Limited | Conditions: Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING